About ABBV-744 as a potential therapeutic option for aggressive cancers
In Segment C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Participants will get treatment right until ailment progression or the individuals are unable to tolerate the study drugs.Ubiquitin-related proteins that control the stability of essential Tremendous enhancer-mediated p